Pfizer is currently one of the most probable vaccine for COVID-19 pandemic. The scientists behind this revolutionary vaccine demanded emergency approval.
The vaccine has been developed with breathtaking speed — just 10 months after the genetic code of the novel coronavirus was first sequenced.
The announcement had been expected for several days, after the companies said that a completed study of trials of the product showed it was 95 percent effective in protecting people from infection. The announcement also confirms what BioNTech’s CEO told AFP Thursday.
‘Filing in the US represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,’ Pfizer CEO Albert Bourla said.
The vaccine has been under evaluation for weeks in the European Union, Australia, Canada, Japan and the United Kingdom, the companies said.
‘The companies will be ready to distribute the vaccine candidate within hours after authorization,’ their statement said.
The Food and Drug Administration has not said how long it will take to study the vaccine data, but the government expects to give the green light for the vaccine in the first two weeks of December.
The European Union could also move quickly on the Pfizer-BioNTech vaccine, perhaps as soon as the second half of December, according to European Commission president Ursula von der Leyen.